Acinetobacter baumannii Vaccines
Creative Biolabs is a world leader in the field of bacterial vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against disease caused by Acinetobacter baumannii and guarantee the finest results for our customers all over the world.
Acinetobacter baumannii (A. baumannii) is a typically short, almost round, rod-shaped, aerobic, pleomorphic, and non-motile Gram-negative bacillus. It is a highly contagious bacterium that can cause serious and sometimes life-threatening infections. These infections could occur in the lungs, blood, and brain. The bacterium is a water organism and preferentially colonizes aquatic environments. It is often cultured from hospitalized patients' sputum or respiratory secretions, wounds, and urine. It can be an opportunistic pathogen in humans and spread by direct contact and may be found on skin or in food, water, or soil. Vaccine is one of the most effective measures for infection control by multi-drug resistant Acinetobacter A. baumannii.
Live Vaccines
It is that proved D-glutamate is an essential component of bacterial peptidoglycan and is found in the cell wall of virtually all bacteria. A vaccine to generate D-glutamate auxotrophic has been developed for A. baumannii protection. After vaccination in mice, this vaccine showed virulence attenuation and self-limited growth, as well as elicit functional, cross-reactive antibodies, and cellular immunity. In addition, deletion of the thioredoxin gene (trxA) from A. baumannii could result in a 100-fold increase in 50% lethal dose in a systemic challenge murine model. Therefore, use of this attenuated strain as a live vaccine against A. baumannii is possible. The vaccination stimulates a robust antibody response with a minimal T-cell mediated response irrespective of vaccination route.
Outer Membrane-Based Vaccines
Outer membrane lipoprotein A, a small protein A (SmpA) homologue in Pseudomonas aeruginosa, is considered to be important in the formation and maintenance of cell membrane structure and integrity, and is a virulence factor in Gram-negative bacilli. Phospholipase D (PLD) plays an essential role in the process of transmission of pathogens via blood and it has been implicated to be a virulence factor of A. baumannii. Here we use SmpA and PLD as appropriate vaccine candidates against A. baumannii infection. In conclusion, it was identified that SmpA and PLD are highly immunogenic proteins and potential antigen candidates for the development of effective vaccines or to prepare antisera to mitigate A. baumannii infection.
DNA Vaccines
The DNA sequence of OXA-51 gene which is a predominant gene in all Acinetobacter strains showed 98% homology with A. baumannii and also showed less homology percentage with other strains of Acinetobacter. OXA-51 can be a potential candidate as the A. baumannii ghost (ABG) and induced differential leukocyte count, cell viability, slide agglutination, passive hemagglutination, E-rosette test, phagocytosis, and opsonophagocytosis, may be an effective approach for preventing A. baumannii infection. A recombinant fused protein named OmpK/Omp22 for mice immunization provided significantly greater protection against A. baumannii challenge than those immunized with either of the two proteins individually. NlpA is one of the important antigenic factors in biogenesis of outer membrane vesicles and research was aimed to clone and express nlpA gene in eukaryotic HDF cells as DNA vaccine. This recombinant construct was capable to induce the immune response in immunized mice. These findings give various options to design the DNA vaccine candidates against A. baumannii.
Glycoconjugate Vaccines
A. baumannii encodes more than 1500 proteins, any of which alone or in combination can theoretically serve as targets for immune recognition. Immunization of mice with an A. baumannii lpxD mutant strain that completely lacks LPS gene induced a comparable protective immunity to that induced by the parental strain with intact LPS. In addition, OmpA is regarded as the most promising one because OmpA is an important virulence factor in the pathogenesis of A. baumannii infection and is highly immunogenic in mice and humans. These provide a new concept for the development of glycoconjugate A. baumannii vaccines.
Creative Biolabs is a highly proactive, robust, and diversified company with a strong, scientifically-proven background of bacterial vaccine development. We have experts who are able to help you with the vaccine development against disease caused by Acinetobacter baumannii. If you are interested in our services, please contact us for more details.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
